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RIASSUNTO 
 
 
Le matrici acellulari rappresentano uno scaffold promettente per l’ingegneria 
tessutale. Infatti, la matrice extracellulare costituisce un supporto sito-specifico che 
favorisce la crescita e il differenziamento delle cellule di qualsiasi organo.  
Ad oggi, le tecniche dell’ingegneria tessutale sono utilizzate sia per lo sviluppo ex 
vivo di sostituti tessutali, che per studiare la proliferazione e la differenziazione 
delle cellule quando si trovano all’interno di uno scaffold tridimensionale.  
In questo lavoro di tesi, i due seguenti progetti sono andati a valutare entrambe le 
potenzialità di matrici acellulari tessuto-specifiche: 
1- valutazione della capacità della matrice acellulare di indurre il 
differenziamento di progenitori renali da fluido amniotico in cellule renali 
mature; 
2- valutazione della matrice acellulare per la sostituzione di vasi sanguigni. 
1- La matrice acellulare renale è stata utilizzata per valutare la capacità 
differenziativa di progenitori renali da fluido amniotico in modo da valutarne 
una futura applicazione terapeutica. I progenitori renali sono stati seminati 
sulla matrice acellulare renale, che, in vitro, ne ha promosso la proliferazione, 
il mantenimento del fenotipo podocitario e la differenziazione in cellule 
tubulari. Per valutare in vivo il potenziale differenziativo di queste cellule, la 
matrice da sola o ripopolata con le cellule è stata impiantata all’interno di un 
rene di topo nudo. I progenitori renali si sono ulteriormente differenziati, si 
sono integrati all’interno delle strutture tubulari dell’ospite e hanno 
promosso la migrazione di cellule differenziate murine all’interno dello 
scaffold.  
2- La matrice acellulare di aorta è stata utilizzata per lo sviluppo di sostituti 
vasali. Nonostante vasi autologhi o costituiti di polimeri sintetici vengano già 
utilizzati nella pratica clinica per la ricostruzione di vasi di piccolo diametro 
(<5 mm), numerosi sono gli svantaggi legati al loro utilizzo, quali l’iperplasia 
della tonaca intima e la degenerazione arteriosclerotica. Lo scopo di questo 
studio è stato quello di sviluppare sostituti vasali utilizzando come scaffold 
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vasi decellularizzati. Matrici acellulari da sole o ripopolate con cellule 
endoteliali da microcircolo sono state impiantate nell’aorta di ratto Lewis. 
Come osservato negli impianti di sola matrice acellulare, la mancanza della 
copertura endoteliale portava all’iperplasia dell’intima e all’aumento di 
incidenza dei processi trombotici, sottolineando la necessità di 
reendotelizzare in vitro il vaso decellularizzato prima dell’impianto in vivo. 
Infatti, i sostituti vasali costituiti da matrice acellulare e cellule endoteliali da 
microcircolo hanno dimostrato di avere una buona resistenza al flusso e non 
presentavano trombi al loro interno. Sebbene questi vasi fossero assottigliati 
e mostrassero una leggera iperplasia della tonaca intima, questo approccio 
presentava due principali vantaggi: permetteva di ottenere sostituti vasali in 
un tempo clinicamente utile ed eliminava la necessità di rimuovere vasi sani 
per ottenere cellule endoteliali autologhe. 
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ABSTRACT 
 
 
Acellular matrices (AMs) seem to be a very promising scaffold in Tissue Engineering 
(TE) and can be considered as temporary inductive site-appropriate templates to 
support the growth, differentiation, and function of the parenchymal cell population 
of each organ. Nowadays, TE techniques are used both to develop tissue substitutes 
ex vivo and as reliable tool to investigate cell behaviour, differentiation and 
proliferation in 3-dimentional environments.  
In this work the following two different projects have investigated both 
potentialities using tissue-specific AMs: 
1- influence of AMs on differentiation of kidney progenitor cells from amniotic 
fluid into mature renal cells; 
2- AMs as biomaterial to develop vessel substitutes. 
1- Kidney AMs (KAMs) were used to evaluate the differentiation of kidney 
progenitor cells from amniotic fluid into mature renal cells in order to better 
understand whether they could be suitable for future application in therapy. 
Renal progenitors were seeded into KAMs, which led them to proliferate, 
maintain podocyte phenotype and differentiate into tubular cells in vitro. To 
further evaluate the differentiative potential of KAMs, grafts composed of 
KAM with or without cells were intrarenal implanted into nude mice. In vivo, 
progenitors from amniotic fluid expressed mature renal markers, attracted 
inside KAMs differentiated murine cells and integrated into host structures. 
2- Although autologous vascular grafts and artificial materials have been used 
for reconstruction of small diameter (<5 mm) blood vessels, the poor 
availability of vessels and the occurrence of intimal hyperplasia and 
progressive atherosclerotic degeneration represent shortcoming of these 
vascular prostheses. Therefore, this study aimed to develop AM-based 
vascular grafts. Both aorta AMs (AAMs) alone and AAMs previously 
reendothelized with skin microvascular endothelial cells (ECs) were in vivo 
implanted and analyzed. The lack of reendothelization, leading to intimal 
hyperplasia and increased incidence of thrombosis observed in AAMs grafts, 
  4 
have indicated the need to provide in vitro an endothelial coverage of 
decellularized tissue. Indeed, grafts composed of AAM and skin 
microvasculature ECs shown good patency and no thrombi. Although these 
grafts appeared narrowed and a moderate hyperplasia has been detected in 
the inner layer, they presented two main advantages: they were obtained 
into a clinically relevant time frame and eliminated the need to remove 
healthy vessels for collecting autologous ECs.  
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INTRODUCTION 
 
 
1. TISSUE ENGINEERING 
End-stage disease is a serious, growing and costly issue. At the present, definitive 
treatment for end-stage organ failure is allogenic transplantation. However, a 
combination of unremitting demands, expensive and potentially dangerous 
immunosuppression, and the requirement that donor organs be physiologically 
viable means that the clinical need will never be met and many patients on 
transplantation waiting list will die before a donor organ becomes available. 
Patients fortunate enough to receive a donor organ endure life-long 
immunosuppressive therapies with its associated morbidity and are at risk of acute 
or chronic organ rejection (Badylak et al, 2012). 
Langer and Vacanti postulated that living organs might be designed and built based 
on the principle of biological science and technologic advances in the engineering 
disciplines (Langer et al, 1993).  This new field, named Tissue Engineering (TE), 
combines aspects of cell biology and transplantation, material science and 
biomedical engineering to develop biological substitutes that can restore and 
maintain the function of damaged tissue and organs.  
TE strategy could be used also as a reliable tool to investigate cell behaviour, 
differentiation and proliferation pathways in 3-dimentional environments, in order 
to decrease in vivo experiments. Besides, scaffolds miming native supports could be 
used in vitro as an alternative approach to improve cells proliferation and 
differentiation. 
The two basic components of this strategy are cells and biomaterials. The 
introduction of cells is designed to stimulate regeneration, promote vascularisation 
and supplement the production of hormones and growth factors. Biomaterials, 
natural or synthetic scaffolds, guide the direction of new tissue growth, provide the 
proper spatial environment to restore tissue structure and function and may 
introduce bioactive molecules, attracting cells and growth factors from the host 
after implantation (Atala, 2012). 
1.1 Cell types used in TE 
Depending on the organ to be restored, several cell types are currently investigated 
in order to obtain a tissue that can perform the appropriate physiologic/metabolic 
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duties. Briefly, cells used in TE can be tissue-specific differentiated cells or stem 
cells.  
1.1.1 Tissue-specific differentiated cells 
These cells are harvested from the specific organ to be regenerated, cultured ex vivo 
and used in the same patient without rejection, in an autologous manner. One of the 
limitation of this technique has been the inherent difficulty of growing specific cell 
types in large quantities.  
1.1.2 Stem cells 
The interest about stem cells has been increasing over the past years, since their 
discovery in the early ’90s. Stem cells might be a promising tool for regenerative 
purposes because of their capability to become almost any cell of an adult organism. 
It is universally accepted that a stem cell possesses two fundamental 
characteristics: long term self-renewal and pluripotentiality.  
Self-renewal describes the unique capability of these cells both to reproduce itself 
indefinitely and to produce cell progeny that matures into more specialized, organ- 
specific cells.  
Pluripotentiality is defined as the ability of a stem cell to give rise to different 
tissues. Based on their capability to differentiate into different cell types, stem cells 
are divided into different categories. Pluripotent stem cells are defined by the ability 
to differentiate, under certain stimuli from the surrounding environment, into cells 
of all the three germ layers and germ cells. A cell is defined as multipotent if can give 
rise to more than one cell type and unipotent if it can differentiate into one cell type.  
Embryonic Stem Cells 
Embryonic Stem Cells (ESCs) are collected from the Inner Cell Mass (ICM) of the 
blastocyst at five days from the fertilization of the egg. The blastocyst includes three 
structures: the trophoblast, which is the cell layer surrounding the blastocyst; the 
blastocoel, which is the hollow cavity inside the blastocyst; and the ICM, which is a 
group of approximately 30 cells at one end of the blastocoel. ESCs are defined as 
pluripotent. For this reason, ESCs have been widely investigated for their wide 
capability to differentiate into any cell line of the body, being a reliable tool for cell 
development and differentiation pathway studies. However, their clinical 
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application is limited by ethical issues, their origin that can evoke an immune 
response, and   the potential to form teratomas.  
Fetal Stem Cells 
Fetal Stem Cells can be isolated from two different sources, the fetus proper and the 
supportive extra-embryonic structures (amniotic fluid, Wharton’s jelly, placenta 
and amnion).  
Several population have been obtained from extra-embryonic structures; fetal cells 
grow well in culture, are able to differentiate into multiple cell types and may be 
less likely to be rejected following transplantation. Besides, the extracorporeal 
nature of fetal stem cell source facilitates isolation, increases the number of stem 
cells that can be obtained and overcomes ethical concerns (Marcus et al, 2008). 
In particular, De Coppi et al (2007) have shown that amniotic fluid contains a novel 
type of stem cell which is capable of being maintained in an undifferentiated state in 
culture for long periods and can be induced to differentiate into many different cell 
types. Their pluripotency, high proliferation rates, multi-differentiation capability 
and lack of teratoma formation when injected in vivo make them attractive 
candidates for cell sourcing. In addition, there are no serious ethical issues with the 
use of these cells, which is an advantage over other stem cells such as ESCs and 
induced Pluripotent Stem cells (iPS). Very recent exciting results using amniotic 
fluid stem (AFS) cells or AFS-combined engineered tissues for therapeutic 
applications have encouraged their use in the field of regenerative medicine in more 
advanced and broader manners (Joo et al, 2011). 
Adult Stem Cells  
Adult Stem Cells (ASCs) are located within the tissues of the adult body. Under 
specific stimulation, they undergo differentiation and replace the loss of cells in an 
injured compartment. A specific organ localization, called niche, is thought to 
harbor the stem cells in an environment that protects cells from differentiation.   
Examples of ASCs are hematopoietic stem cells (HSCs). HSCs, localized within the 
bone marrow, are the most important adult stem cell line. HSCs are commonly used 
for the treatment of leukemia diseases. Furthermore, HSCs were shown to 
differentiate into myocites, endothelial cells, hepatocytes and epithelial cells of liver, 
gut, lung and skin. 
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In bone marrow another population, called bone marrow stromal stem cells (BM-
MSCs) shows to differentiate into mesenchymal lineages. BM-MSCs were shown 
capable to differentiate in vitro into adipocytes, chondrocytes, muscle cells, tendons, 
osteoblasts and endothelial cells. In vivo experiments reported successful 
differentiation of mouse BM-MSCs into brain astrocytes, glial cells, CNS cells, 
hepatocytes, endothelial and myocardial cells in adult mice (Raff, 2003). 
Somatic Cell Nuclear Transfer and Induced Pluripotent Stem Cells 
Scientific knowledge allows us to modify cell genetic background and gene 
expression and to obtain different types of exogenous stem cells. Somatic Cell 
Nuclear Transfer (SCNT) cells were derived from the injection of an endogenous 
somatic cell nucleus within an oocyte. The result was the creation of a pluripotent 
cell, capable of being implanted in utero or used to retrieve new stem cell lineages. 
iPS cells were obtained with insertion of pluripotent genes within the DNA of a 
somatic cell. Retroviral introduction of transcription factors OCT-4, SOX-2, KLF4 and 
MYC induced pluripotency within somatic cells. Recent studies have shown that 
OCT-4 and SOX-2 could be combined with other genes to produce iPS cells. iPS cells 
were able to participate to the embryonic development when injected in a 
blastocyst. 
However, the efficiency of the reprogramming process is jeopardized by the low 
yield of transfection and the long time of reprogram. Moreover, the employment of 
viral delivery system like lentiviral vectors might increase the risk of insertions of 
foreign genetic sequences in host genome thus causing gene mutations and cell 
transformation. Recently, small molecules able to modulate specific targets in 
receptor signaling and epigenetic machinery have been used to improve the 
reprogramming process and/or replace some transcriptional factors, thus partially 
or totally avoiding the host genome involvement. In this context, histone 
deacetylase inhibitors (HDACIs), such as valproic acid (VPA), thricostatin A (TSA), 
and suberoylanilide hydroxamic acid (SAHA), induce the hyperacetylation of 
histones modifying chromatin moiety and affecting gene expression (Huangfu D et 
al, 2008). 
1.2 Biomaterials used in TE 
The biomaterial itself should be able to i) naturally provide cell attachment and 
support; ii) dispose of sufficient area to allow cell proliferation; iii) develop the 
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ability of shaping specific structures; iv) in vivo degrade without releasing toxic 
materials; iv) allow tissue remodelling and resorption avoiding foreign body 
reaction and iv) allow ingrowth of host cells. Furthermore, it can also provide 
mechanical support against in vivo forces such that the predefined 3-dimensional 
structure is maintained during tissue development. Two classes of biomaterials 
have been used for engineering tissues and organs: synthetic polymers and natural 
biomaterials.  
Synthetic biomaterials 
Synthetic biomaterials present the following advantages in comparison with natural 
scaffolds: tightly control of physical properties, such as mechanical strength, 
degradation rate and pore size, and production with fewer batch-to-batch 
variations. One drawback of the synthetic polymers is lack of biologic recognition, 
although a number of groups are attempting to design synthetic scaffolds, which 
incorporate proteins or other molecules to assist in recognition (Atala, 2012). So, 
adhesion molecules can be adsorbed or covalently bound to the surface of scaffold. 
Extracellular matrix (ECM) adhesion proteins, such as fibronectin, collagen and 
laminin, present some disadvantages in the view of medical applications. They can 
elicit immune response, since they are isolated from other organisms and need to be 
purified. They also need to be refreshed continuously, because they are object of 
proteolytic degradation.  On the contrary, small peptides, containing only the 
sequence responsible for cell adhesion, are characterized by higher stability, easier 
characterization, and possibility to be packed with a higher density on surfaces. 
Thus, their use can overcome most of problems connected to ECM proteins. For 
example, small peptides can be designed to contain RGD sequence (Arg-Gly-Asp) 
which mediates cell-adhesion via cell membrane integrin receptors, or heparin 
binding sequences able to interact with cell membrane heparin sulphate 
proteoglycans.   
The major classes of synthetic biomaterials include glycolic acid derivatives (PGA), 
lactic acid derivatives (PLA), and other polyester derivatives (as poly(lactic-co- 
glycolic acid, PLGA). These polymers have gained Food and Drug Administration 
approval for human use in a variety of applications, including sutures. The 
degradation products of PGA, PLA, and PLGA are nontoxic, natural metabolites that 
are eventually eliminated from the body in the form of carbon dioxide and water. 
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Because these polymers are thermoplastics, they can easily be formed into a 3-
dimensional scaffold with a desired microstructure, gross shape, and dimension by 
various techniques. Electrospinning has been used to quickly create highly porous 
scaffolds in various conformations.  
Natural biomaterials 
Natural scaffolds are made up of protein or carbohydrates with particular 
biochemical, mechanical, and structural properties. They can be derived from plant 
or animal sources, and are mostly found to be both biocompatible and 
biodegradable. These scaffolds have an increased advantage due to the presence of 
multifunctional groups on scaffold surfaces, which can be tailored according to 
specific applications. Examples of natural biomaterials are collagen, chitosan, 
hyaluronic acid, fibrin, and gelatin, which have been applied for the repair and 
reconstruction of several tissues. Even though natural scaffolds have been applied 
for a variety of tissue-engineering applications. Limitations include the inability to 
control or modify the chemical and biologic properties of these scaffolds for specific 
applications (Patel et al, 2008). 
Among natural biomaterials, acellular tissue matrices (AMs) have been successfully 
used both in pre-clinical animal studies and in human clinical applications. AMs are 
prepared by removing cellular components from tissues and are commonly used to 
facilitate the constructive remodeling of a variety of tissues.  
The preparation of a 3-dimensional, AM scaffold from an intact mammalian organ 
requires several processing steps, each of which can markedly affect the structure 
and composition of the biomaterial and the associated host response that these 
scaffolds will elicit when utilized as templates for organ reconstruction. The 
effective removal of antigenic epitopes associated with cell membranes and 
intracellular components of organs and tissues is necessary to avoid, or at least 
minimize, adverse immune responses by allogeneic or xenogeneic recipients. The 
decellularization process that must retain the native composition and structure of 
the associated matrix, typically involves exposure of the tissue to detergents, 
proteases, and chemicals by perfusion of the native vasculature. Commonly used 
protocols include the perfusion of chemical or enzymatic agents and physical 
methods, such as sonication, freezing, and thawing, coupled to shaking in order to 
disrupt cell membranes, release cell contents, and facilitate the rinsing and removal 
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of cell remnants from the ECM. Combinations of these various approaches are 
typically used to maximize the efficiency of the process for each tissue and organ. 
Organ decellularization may involve the delivery of chemical agents by vascular 
perfusion. As a general rule, the use of detergents and chaotropic agents such as 
TRITON X, sodium dodecyl sulfate, and sodium deoxycholate should be minimized 
whenever possible to avoid damage to the ultrastructure and composition of the 
native ECM. 
The specific composition varies depending on the source tissue/organ from which 
the AM is prepared. ECM proteins are arranged in a unique, tissue-specific, 3-
dimensional ultrastructure and are ideally suited to the tissue or organ from which 
the AM is harvested. The peculiar structure and composition can be largely 
preserved by the appropriate use of processing steps required for the 
decellularization of the tissue. In general, however, AMs from all organs consists 
mainly of type I collagen, glycosaminoglycans, fibronectin, laminin, and various 
types of growth factors. Furthermore, AMs maintain organ-specific structures, such 
as the collagen type IV and laminin-rich basement membrane of blood vessels. 
Ultrastructural characteristics of the matrix appear to play important roles in 
modulating the cell behaviour either by regulating cell ability to migrate into and 
attach to specific locations within the scaffold or by influencing tissue-specific 
phenotypic differentiation. Cell proliferation, migration, and differentiation, as well 
as processes such as angiogenesis are mainly regulated in part by cell-signaling 
mechanisms involving soluble molecules. Thus, the biologic signaling activities 
provided by degradation products of AMs have a marked effect on the host-
remodeling response following in vivo implantation. These scaffold materials can be 
considered as temporary inductive site-appropriate templates to support the 
growth, differentiation, and function of the parenchymal cell population of each 
organ (Badylak et al, 2011).  
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2. TISSUE ENGINEERING IN KIDNEY DISEASE 
2.1 End Stage Renal Disease and Chronic Kidney Disease   
End Stage Renal Disease (ESRD) is a condition of chronic and progressive injury of 
the kidney, leading to a complete failure of the renal system. ESRD usually occurs 
when renal functionality is less than 10% of normal activity (Perin et al, 2008). 
According to the 2007 United States Renal Data System, the number of United States 
patients in treatment for ESRD was 400,000, with more than 20,000 waiting for 
organ transplantation. Predictions for the year 2020 are showing an increase in 
patients undergoing dialysis and in need of kidney replacement. Progression to 
ESRD can be simplified within two major processes known as Acute Kidney Failure 
(AKF) and Chronic Kidney Disease (CKD).  
AKF is characterized by sudden and fast kidney function deterioration. Pathological 
kidney functionality is characterized by a decrease in filtration rate, starting from 
previously called pre-renal acute kidney injury and up to unresponsiveness. Kidney 
stones, infections, cancer or drug intoxication can be causes for AKF (Lameirea et al, 
2008). Common treatments to improve renal perfusion increase cardiac output, 
replenish the circulating volume, enhance cardiac inotropy, and induce 
vasoconstriction. About 4% of all critically ill patients with AKF will require dialysis. 
CKD is recognized as a major health problem affecting approximately 13% of the 
United States population. Numbers of prevalent CKD patients will continue to rise, 
reflecting the growing elderly population. CKD is defined as the presence of kidney 
damage, manifested by abnormal albumin excretion or decreased kidney function 
that persists for more than 3 months. Typically, kidney function is quantified by 
glomerular filtration rate (GFR), the rate at which an ultrafiltrate of plasma is 
produced by glomeruli per unit of time, and is the best estimate of the number of 
functioning nephrons or functional renal mass. The early stages of CKD (GFR 
between 90 and 60 mL/min per 1.73 m2) are manifested by kidney damage and are 
generally asymptomatic: the kidney functions normally but the risk for progressive 
disease is significant. As kidney disease worsens, renal function begins to 
deteriorate (GFR between 29 and 15 mL/min per 1.73 m2). Eventually, kidney 
failure (GFR < 15 mL/min per 1.73 m2) occurs and kidney replacement therapy is 
required (NKF-KDOQI, 2007). Common origins for CKD are pathologies affecting the 
kidney compartment like analgesic nephropathy, glomerulonephritis, kidney stones, 
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obstructive uropathy and reflux nephropathy, lupus, and polycystic kidney disease, 
genetic malformations or diseases affecting other organs, like diabetes and 
hypertension. Complications derived from CKD are various. The loss of function is 
usually coupled with an increase of fibrosis, amyloid deposition and glomeruli 
destruction. Major sequelae of CKD include continued progression of the disease 
and development of kidney failure requiring kidney replacement therapy, 
development and/or progression of cardiovascular disease, anemia, and bone 
disease.  
There are several therapeutic and pharmacological tools used by clinicians to slow 
the progression and symptoms of ESRD, but the only effective treatments up to now 
are dialysis and transplantation.  
Currently, in the early stages, CKD drug therapy is limited to administration of 
antihypertensive agents to decrease blood pressure, and consequentially decrease 
the risk of injury provoked by high blood pressure, and limit proteinuria. Although, 
pharmacological treatments are a good start point to treat kidney disease, 
mechanisms leading to ESRD are multiple and very complex and the administration 
of one or more drug is not enough to treat and cure the CKD. Even if on 
pharmacological therapy many patients eventually require renal replacement 
therapy, or dialysis. Dialysis is a clinical procedure that substitutes the loss function 
of the kidney for what concerns the blood purification. Dialysis is not a complete 
replacement therapy because it provides only blood filtration while kidney is an 
endocrine organ responsible for the secretion of hormones that are critical in 
maintaining hemodynamics (renin, angiotension II, prostaglandins, nitric oxide, 
endothelin, and bradykinin), red blood cell production (erythropoietin), and bone 
metabolism (1,25-dihydroxyvitamin D3 or calcitriol). In addition, although life-
sustaining, dialysis does not provide a good quality of life and several side effects 
may occur such as hypotension, arrhythmia, and complications of vascular access 
placement. 
 Kidney transplantation from a live donor is the first choice for eligible patients who 
require renal replacement therapy: it has lifestyle advantages and is cheaper than 
dialysis. Nonetheless, availability of donor kidneys is very limited. Many adults on 
the deceased donor waiting list will die on dialysis before they receive an organ. 
Thanks to the use of immunosuppressive drugs, by now it is possible to transplant 
not well-matched organs. However, immunosuppression takes its toll in both the 
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short and long term. In the short term, infection is a particular concern, especially 
with viruses such as cytomegalovirus, while, in the long term, the incidence of most 
cancers is increased in patients who are immunosuppressed.  
2.2 Renal regenerative medicine 
In order to overcome the limits of current therapies, scientists and clinicians have 
looked for alternative approaches for CKD management. In the last years TE has 
grown as an alternative for several diseases and the possibility of restoration of 
kidney tissue using cells, regenerative factors, biomaterials, or combination of these 
three, is approaching (Dankers et al, 2011).   
 
 
 
 
 
 
 
 
 
2.2.1 Cell-based approaches 
Many investigators have searched for small subpopulation of resident stem cells 
that might be responsible for the rapid proliferative response after renal injury 
while in healthy kidney they stay in a dormant state. In rat kidneys renal stem cells 
were discovered among tubular epithelial cells and in the papilla and they have 
been shown to differentiate into renal tubules when injected under the renal 
capsule. However, the clinical significance of these observations is still unclear 
(Gupta et al, 2006).  
BM-MSCs seem to contribute to renal regeneration. After damage, they can replace 
tubular, mesangial, interstitial, endothelial cells and podocytes, but the relative 
contribution is very low and does not exceed a few percent of the total proliferating 
cell fraction. However, they can produce a variety of paracrine factors, such as VEGF 
(Vascular Endothelial Growth Factor), IGF (Insulin-like Growth Factor), bFGF 
(Fibroblast Growth Factor), HGF (Hepatocyte Growth Factor) and TGFβ 
Renal regenerative medicine. Three possible strategies, or combination of them that can be applied to 
regenerate and/or engineer renal tissue (Dankers et al, 2011) 
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(Transforming Growth Factor β) that can enhance repair. Despite the optimism 
about their use for renal regeneration, they have been shown to be ineffectiveness 
in case of kidney fibrosis and to differentiate towards myofibroblasts producing 
excessive collagens.  
A number of studies have explored the possibility to generate renal epithelia from 
ESCs. After injection, ESCs have been shown to integrate into the tubuli of 
developing kidneys. However, differentiation towards a specific cell lineage is very 
complicated; it depends on factors secreted in the microenvironment and it is 
difficult to mimic in vitro (Dankers et al, 2011). Besides, there are still several 
ethical concerns about their clinical use.  
Perin et al (2010) have shown that amniotic fluid could represent a novel source of 
stem cells that may function to modulate the kidney immune milieu in AKF. When 
injected into the damaged kidney, amniotic fluid stem cells provided a protective 
effect, ameliorating AKF in the acute injury phase by decreasing the number of 
damaged tubules and apoptosis therein and by promoting proliferation of tubular 
epithelial cells. 
Recently, Sedrakyan et al (2012) demonstrated that stem cells from amniotic fluid 
could be beneficial also in kidney diseases characterized by progressive renal 
fibrosis. Amniotic fluid stem cells did not differentiate into podocyte-like cells, but 
the mechanism of renal protection was probably the paracrine/endocrine 
modulation of both pro-fibrotic cytokine expression and recruitment of 
macrophages to the interstitial space.  
Da Sacco et al (2010) demonstrated that human amniotic fluid provides a new 
source for renal progenitor cells. These cells were grown in culture for several 
passages and expressed typical renal markers. The identification of specific renal 
progenitors suggests that human amniotic fluid may represent a valuable new 
source of cells for regenerative therapies that may be applicable to a broad range of 
renal disease. 
2.2.2 Growth factor-based approaches 
Exogenous growth factor administration to enhance renal regeneration has been 
studied in large detail. The up-regulation of growth factor genes promotes renal 
repair processes. Systemic injection of  EGF and HGF successfully enhanced 
recovery and survival after acute kidney injury in animal models (Hammerman et 
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al, 1994). However, a major disadvantage is that these therapies might lead to 
unwanted side effects in other organs, especially when the drug is administered 
systemically.  
2.2.3 Biomaterial-based approaches 
In the future, a possible solution for patient with CKD, besides dialysis or 
transplantation, might be a tissue-engineered kidney, which should be able to 
replace all kidney functions, including endocrine and metabolic activities.  
A new approach is the bioengineering of an extracorporal renal device using a 
membrane and a single renal cell type that has to form a monolayer of cells in order 
to replace critical endocrine and metabolic renal function. Such a bioartificial kidney 
might be applied as a renal assist device and exert its function when placed in series 
with a conventional hemodialysis module (Aebischer et al ,1987).   
Humes et al (1999) designed a membrane composed of human epithelial cells in a 
hollow fiber cartridge that was characterized both by pore selectivity and hydraulic 
permeability as the native kidney. The transport of electrolytes was absent but the 
activity of renal epithelial cells could attenuate the consequences of septic shock by 
modulating plasma cytokine levels.  
Few experiments have been conducted where renal cells were cultured in vitro, 
seeded into a polyglycolic acid polymer scaffold and subsequently implanted into 
athimic mice. Over time, formation of nephron-like structures was observed within 
the polymer (Amiel et al, 2000). These preliminary results, when improved, could 
easily be used to produce 3-dimensional functional renal structures that can be 
used in ex-vivo or in vivo filtering units. Yoo et al (1996) harvested mouse renal cells 
and seeded them onto a polycarbonate tube. This device was connected at one end 
to a silastic catheter which terminated into a reservoir, and then implanted 
subcutaneously in athymic mice. Histological examination demonstrated extensive 
vascularization as well as formation of glomeruli and highly organized tubule-like 
structures. Nonetheless, since adult cells are completely differentiated and their 
response to growth factors can be absent or different from cells in the developing 
kidney, the seeding and the integration of these systems may fail or be partial.  
Therefore, whole-organ approaches, such as reseeding of AMs with stem cells have 
been investigated. Ross and colleagues (2009) infused mouse ESCs through the 
renal artery and the ureter into an isolated rat renal AM and showed proliferation 
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and cell-specific differentiation of the stem cells within the glomerular, vascular and 
tubular compartments. In an other study acellular scaffolds with maintained 
expression patterns were reseeded with cells obtained from donor kidneys of non-
human primate and fetal kidney cells. AMs demonstrated the capacity to support 
cells attachment and migration, promoting cell repopulation (Nakayama et al, 
2010). At the present, much work needs to be done for ex-vivo kidney regeneration 
with AMs and cell therapy approaches to become a viable clinical option.  
 
3. TISSUE ENGINEERING IN VASCULAR DISEASE 
3.1 Vascular disease 
Vascular disease can be divided into Coronary (CAD) and Peripheral Artery Disease 
(PAD). 
CAD, characterized by anatomic or functional alterations of coronary artery, can be 
congenital, due to a birth malformation and rather rare, or acquired, as result of a 
narrowing of the blood vessels. It is the leading cause of death worldwide. 
PAD refers to the obstruction of arteries that carry blood to the legs, arms, stomach 
or kidneys. There are two types of PAD:  
- functional PAD doesn't involve defects in the structure of blood vessels that are 
not physically damaged. This disease has often symptoms related to “spasm” that 
may come and go and it can be caused by temperature, emotional stress or smoking. 
- organic PAD is caused by structural changes in the blood vessels. Examples could 
include inflammation and tissue damage. It can be caused by fatty buildups 
(atherosclerosis) in the inner wall of arteries which block normal blood flow. 
3.2 Vascular disease therapy and vascular regeneration 
PAD management includes lifestyle changes, medicines or both. Currently 
pharmacological therapy is limited to the administration of antiplatelet agents and 
cholesterol-lowering agents (statins). When the drug therapy is not enough, 
angioplasty or bypass surgery may be needed.  
Coronary and peripheral artery bypass grafting is commonly used to relieve the 
symptoms of vascular disease. The grafts usually consist of either mammary artery 
or saphenous vein harvested from the patient. However, the supply of native vessels 
may not be sufficient for multiple bypass or repeat procedures. Furthermore, 
saphenous vein in the elderly patients is prone to thrombi, neointimal formation, 
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atherosclerosis or aneurysm when transplanted into high-pressure arterial sites. 
Thus, the use of materials other than arterial or venous conduits is required. 
Synthetic vascular prostheses, such as Dacron fabric grafts and expanded 
polytetrafluoroethylene (ePTFE), have been developed to overcome the limited 
supply of native graft materials. They perform reasonably satisfactorily in high-flow, 
low-resistance conditions such as the large peripheral arteries, but they are not as 
suitable for small calibre arterial reconstructions (e.g. coronary or lower leg 
circulation). Indeed, they are prone to thrombus induction, embolism and occlusion, 
may harbour bacteria (resulting in graft infection) and may act as a foreign body in 
the patient. They are also associated with poor healing, lack of compliance and 
excessive intimal hyperplasia, particularly near the sites of anastomosis (Thomas et 
al, 2003). Overall, synthetic grafts are not suitable for reconstruction of small-
diameter (internal diameter <5 mm) arteries, due to thrombosis, limited 
reendothelialization, and neointimal hyperplasia, owing mainly to the inherent 
properties of the synthetic materials.   
To avoid the synthetic scaffold limits, some groups have continued to use synthetic 
graft materials as a base for further coats of active materials, such as collagen, fibrin, 
gelatin, Growth Factor Stimulating Factor (GSF) or RGD. Synthetic grafts have also 
been used as a scaffold for supporting cells. However, vascular cells cannot remodel 
ePTFE or Dacron in the same way as they remodel normal ECM components such as 
collagen and elastin and they will detach when exposed to blood flow. An other 
approach is to passivate synthetic grafts with ‘‘biologicals’’ including heparin, 
hirudin, prostaglandins, growth factors, anticoagulant peptide sequences, dextran 
derivatives (to prevent coagulatory events), and antibiotics (to minimise graft 
infections). These molecules are designed to either remain in situ (and thus act 
locally) or to be released into general circulation (Thomas et al, 2003).  
To overcome the limits of current therapies, scientists and clinicians have looked for 
alternative approaches using new biomaterials and cells in order to obtain small 
diameter vessel substitutes.  
3.3 Biomaterials used in vascular regeneration 
For a successful regenerated vascular construct the scaffold material plays a major 
role in all the tissue engineering strategies as it provides the basic framework for 
cell growth. Various materials have been utilized for blood vessel engineering, 
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including synthetic biodegradable polymers and natural biomaterials. Most of these 
scaffolds have also undergone preclinical studies in animals. 
3.3.1 Synthetic biomaterial 
Synthetic scaffold are easily available and inexpensive. These polymers can be 
precisely modified to adjust their degradation rate, biocompatibility and elasticity. 
The most preferred and widely used materials for bioresorbable grafts included 
polyglycolic acid (PGA), polydioxanone (PDO), and polylactide (PLLA) which are 
FDA approved. 
PGA is the most commonly studied scaffold. Its highly porous structure allows 
nutrient diffusion and subsequent neovascularisation. Moreover, it is easily handled 
and fabricated into different shapes. As an approach to develop small-diameter 
vascular conduits, Niklason et al (1999) seeded bovine aortic smooth muscle cells 
(SMCs) on tubular PGA scaffolds and cultured for 8 weeks under conditions of 
pulsatile pressure before seeding with endothelial cells (ECs). They found that the 
endothelialisation was present only in pockets of the graft surface with persistent 
PGA remnants. This failure of endothelialisation may be due to cytotoxic 
degradation products of PGA or lack of cell signalling support. 
Poly ε-caprolactone (PCL) is another popular biomaterial with a slow degradation 
profile, and it is eliminated through macrophage and giant cell encapsulation. 
Therefore, it is most suitable for the design of long-term implantable systems.  
The first clinical application of an artificial vessel based on biodegradable scaffold 
was reported by Shin'oka et al (2001) in a 4-year old girl. A Polycaprolactone–
polylactic acid copolymer tube was reinforced with woven PGA and then seeded 
with the patients own venous ECs. After that, several patients underwent tissue 
engineered graft implantation with cultured autologous venous cells. There was no 
evidence of aneurysm formation, graft rupture, graft infection, or ectopic 
calcification. Similar results were obtained using BM-MSCs (Shin'oka et al, 2005). 
Although synthetic materials are advantageous over the natural polymers in terms 
of strength and tunable degradation characteristics, they also lack the appropriate 
cell signaling cues which mainly limit the cell maturation, differentiation and 
appropriate ECM secretion necessary for tissue regeneration. These materials may 
also lead to cell delamination from the surface which is also a critical issue when it 
comes to luminal endothelialisation and blood shear flow characteristics. 
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Modification of synthetic surfaces by attaching specific cell responsive groups, like 
RGD peptide sequences or heparinized surfaces, is being explored to overcome 
these issues (Thomas et al, 2003). 
3.3.2 Natural biomaterials 
An important alternative to synthetic materials is the use of AMs derived from ex 
vivo tissues. Decellularized biological scaffolds have the advantage of being rich in 
the cell signalling components essential for cell adhesion, migration, proliferation 
and differentiation. Preserved AM components include collagen, elastin and 
glycosaminoglycans. Intact collagen and elastin fibers ensure retention of tensile 
strength and elastic recoil properties, and there is evidence to suggest that they 
inhibit SMC proliferation, an early step of intimal hyperplasia. Glycosaminoglycans, 
which include chondroitin, dermatan, heparan and heparin sulphate, play a crucial 
role in EC adhesion and proliferation, inhibition of SMC proliferation and migration 
following injury or inflammation, in addition to their antithrombotic properties. 
Biological vascular substitutes also display a greater resistance to infection 
compared to synthetic grafts (Yow et al, 2006). 
One notable example of a decellularized tissue that is being used in vascular tissue 
engineering is the small intestinal submucosa (SIS) that is seen to retain angiogenic 
growth factors, such as b-FGF and VEGF. At first, decellularized SIS without any 
modification was used as vascular substitute showing a good patency rate as a 
large-diameter graft (Lawler et al, 1971). After almost 30 years, Huynh and 
colleagues (1999) constructed a scaffold from a collagen-based biomaterial derived 
from SIS and bovine collagen type I. The inner lining was treated with heparin and 
this acellular graft was implanted into rabbit aortas demonstrating promising 
results as small-diameter graft. 
Various other decellularized matrices were also used like bovine ureters, porcine 
carotid artery and aorta and even canine carotid arteries (Clarke et al, 2001; 
Conklin et al, 2002).  Decellularized human umbilical arteries were also implanted 
into nude rats as abdominal aorta interposition grafts which remained mechanically 
intact and patent for up to 8 weeks (Gui et al, 2006). 
However, the luminal surface of these decellularized matrices without EC lining 
carries a substantial risk for thrombosis when exposed directly to the blood flow. 
Hence in recent years, much work has been focused on recreating tissue-engineered 
  21 
vascular grafts by recellularizing biomaterials with host vascular cells prior to 
implantation. Bader et al (2000) used decellularized porcine aortas, which were 
then repopulated with human myofibroblasts and ECs derived from saphenous vein. 
After 2-3 weeks, the graft was fully repopulated and immunologically acceptable to 
the host.     
Although non-human decellularized vessels are very easy to access and promote 
site-specific remodeling and regeneration by the host, they face chances of 
transmission of animal pathogens to human being when considering the clinical 
scenario.  
Alternative vascular substitutes are based on collagen, fibrin or gelatin. Collagen-
based conduit revealed to be fragile and they need a wrapping with a reinforcing 
synthetic polymer. However, the reinforcing materials on account of being 
non-degradable were seen to adversely affect the remodeling response which led to 
loss of compliance in post-implantation period (Matsuda et al, 1995).  
Swartz et al (2005) engineered implantable small-diameter blood vessels based on 
ovine SMCs and ECs embedded in fibrin. These grafts, implanted in the jugular veins 
of lambs, were well integrated into the native vessel and demonstrated patency up 
to 15 weeks, similar blood flow rates and matrix remodeling as the native vessels.  
Another breakthrough in the fabrication of tissue-engineered grafts was the cell 
sheet approach developed by L'Heureux and colleagues (1998) where an innovative 
graft was developed exclusively from cultured human cells. Sheets of SMCs and 
fibroblasts were grown to over-confluence and then assembled over a mandrel to 
form a tubular structure that was subsequently cultured for 6–8 weeks. During this 
incubation period, the autologous cells arranged themselves circumferentially and 
produced large amounts of ECM, thus establishing a structural integrity capable of 
withstanding pressures in excess of 2000 mmHg. The inner lumen of the construct 
was then seeded with ECs to promote non-thrombogenicity. Recently, this 
technology has been translated to clinical use as arteriovenous fistula shunts in 
hemodialysis patients with promising results. Although the robustness and non 
immunogenic nature of self-assembly grafts hold great promise, the primary 
limitation is the amount of time required for culturing the cells. The extended time 
frame raises cost and impairs the ‘off-the-shelf’ capability of such a technology 
(L’Heureux et al, 2007; McAllister et al, 2009). 
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3.4 Cells used in vascular regeneration 
The combination of natural or synthetic scaffold together with vascular cells is 
considered the most promising option. The endothelium is not only a smooth inert 
surface that facilitates laminar blood flow through the blood vessel, but also a 
dynamic organ with an active role in coagulation homeostasis, the sensing and 
transduction of the haemodynamic forces of circulation, and the cell metabolism of 
the vascular wall. For these reasons, surface endothelialization has a great role in 
intermediate the long-term patency and it is crucial to prevent intimal hyperplasia 
and graft occlusion. One aspect of endothelial protection is the physical barrier it 
forms to prevent contact with subendothelial components of the arterial wall and 
activation of the coagulation cascade. The ideal cell source should be non 
immunogenic, functional and easy to isolate and expand in culture. 
The non immunogenic autologous ECs and SMCs isolated from patients themselves 
represent the first choice of cells for tissue engineering. Reports show that ECs, 
SMCs and fibroblasts could be isolated simultaneously and expanded in culture 
from a single and small vein sample (Grenier et al, 2003). However, majority of the 
cells in adult blood vessel are terminally differentiated, have limited proliferation 
potential and lose their function during in vitro expansion.  
Nevertheless, alternative sources to differentiated vascular cells have been looked 
into to avoid the need of surgical harvest of autologous vessel segments and to 
improve upon the proliferation potential of ECs and SMCs. The use of stem cell is an 
exciting field of research for vascular regenerative medicine as these cells are 
capable of self-renewal and differentiation into functional.   
MSCs are a promising cell type for regenerative medicine owing to their easy 
isolation and expansion, their multipotency and their low immunogenicity. MSC 
differentiation towards vascular phenotypes can be distinguished by the expression 
of experimentally identified specific markers or by functional assays. One unique 
advantage of MSCs is their potential for allogenic cell delivery in immunocompetent 
patients (Huang et al, 2008).  
Adipose tissue is a stem cell source for ECs and SMCs. These cells can be harvested, 
multiplied and handled easily, efficiently and non-invasively. They have a 
proliferative capacity comparable to BM-MSCs, and morbidity to donors is 
considerably less, requiring only local anesthesia and a short wound healing time. 
Furthermore, human adipose stem cells have been shown to differentiate towards 
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endothelial lineage in the presence of VEGF (Cao et al, 2005). 
Pericytes have recently been shown to express mesenchymal stem cell features. 
Their relative availability and multipotentiality make them a promising candidate 
for vascular regeneration. Pericytes were incorporated into bi-layered elastomeric 
poly(ester-urethane) urea scaffolds and the efficacy of the pericyte-seeded scaffold 
was studied in vivo. After implantation, pericyte-seeded grafs showed a significant 
higher patency rate than the unseeded control (He et al, 2010). 
Progenitor cells such as Endothelial Progenitor cells (EPCs) show great potential for 
use in vascular regeneration. They are easy to obtain from the patient and are easy 
to expand in culture. EPCs are mainly located in bone marrow and could be 
mobilized into peripheral blood by certain growth factors, such as granulocyte 
macrophage colony stimulating factor (GM-CSF) or VEGF. EPCs could be also 
isolated from umbilical cord blood. EPCs can be expanded for over 20 passages 
without losing their differentiation potential. No significant differences have been 
found between EPCs derived from bone marrow, peripheral blood or cord blood in 
terms of cell proliferation and differentiation. Kaushal et al (2001) reported the 
isolation of EPCs from peripheral blood of sheep, their expansion and seeding on 
decellularized porcine iliac vessels to construct an engineered vascular graft. EPC-
seeded grafts remained patent for 130 days as a carotid interposition graft in sheep. 
The EPC-explanted grafts exhibited contractile activity and nitric oxide mediated 
vascular relaxation that was similar to native carotid arteries.  
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AIMS 
 
 
AMs seem to be a very promising scaffold in TE and can be considered as temporary 
inductive site-appropriate templates to support the growth, differentiation, and 
function of the parenchymal cell population of each organ. Nowadays, TE 
techniques are used both to develop tissue substitutes ex vivo and as reliable tool to 
investigate cell behaviour, differentiation and proliferation in 3-dimentional 
environments.  
In this work, the following two different projects have investigated both 
potentialities using tissue-specific AMs: 
1- influence of AMs on differentiation of kidney progenitor cells from amniotic 
fluid into mature renal cells; 
2- AMs as biomaterial to develop vessel substitutes. 
 
1- Evaluation of AMs as scaffold to promote kidney progenitor cells differentiation 
into mature renal cells  
In order to better understand whether renal progenitors derived from human 
amniotic fluid could be suitable for future application in therapy, their behaviour 
and response when cultured onto AM system obtained from murine kidney (KAMs) 
have been investigated. To achieve this goal, renal progenitors were seeded onto 
KAMs and their proliferation and differentiation were evaluated by means of 
immunohystological analysis. Besides, to investigate renal progenitors behaviour in 
in vivo system, repopulated KAMs were intrarenal implanted into nude mice. 
 
2- Evaluation of blood vessel substitutes composed by AMs and ECs  
Although autologous vascular grafts and artificial materials have been used for 
reconstruction of small diameter (<5 mm) blood vessels, the poor availability of 
vessels and the occurrence of intimal hyperplasia and progressive atherosclerotic 
degeneration represent shortcoming of these vascular prostheses. Therefore, this 
study aimed to develop AM-based vascular grafts. 
Rats received either only aorta AM or previously in vitro reendothelized AM as 
abdominal aorta interposition grafts (about 1 cm). After 1 and 3 months from 
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surgery, grafts were explanted and morphologically examined by scanning electron 
microscopy and Movat staining.  
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PART 1: Evaluation of AMs as scaffold to promote kidney 
progenitor cells differentiation into mature renal cells 
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MATERIALS AND METHODS 
 
 
1. KIDNEY ACELLULAR MATRICES 
a- Preparation 
All the procedures described and animal protocols were approved by the IACUC at 
Children's Hospital Los Angeles. IACUC is the Institutional Animal Care and Use 
Committee on charge of overseeing CHLA animal programs, animal facilities and 
policies, ensuring appropriate care, ethical use and humane treatment of animals. 
Both male and female C57BL/6 mice (3 months old) were sacrificed using CO2 
inhalation as recommended by IACUC and both kidneys were collected and rinsed 
with PBS. 
Mouse kidney acellular matrices (KAMs) were prepared by the Meezan method 
(Meezan et al, 1975) with minor modifications. Whole kidneys were processed with 
distilled water for 72 h at 4˚C, 4% sodium deoxycholate (Sigma, St. Louis, MO, USA) 
for 4h and 2,000 kU deoxyribonuclease I (DNase-I) (Sigma) in 1 M NaCl (Sigma) for 
3h. This treatment was repeated four times till the decellularization was completed. 
b- Characterization of KAMs by histological and immunohistochemistry staining 
The lack of cells or cell debris was confirmed histologically. Briefly, KAMs were fixed 
in 10% formalin, neutral buffer phosphate (Polysciences Inc.) for 2 h at RT and 
stored in 70% ethanol at 4°C until processing. Specimens were routinely processed 
as following described: 
1h in 95% ethanol, twice; 
1h in 100% ethanol, twice; 
40 min in toluene; 
overnight toluene/paraffin (50:50) and 
2h paraffin 
After this treatment, samples were included in paraffin in embedding cassette 
(Tissue-Tek) and prepared for sectioning. KAMs were cut in 5 µm sections with a 
Leica RM2235 microtome and let to dry on a slide warmer (Lab-Line) at 37 °C. Once 
dried, sections were ready to use for histological and immunostaining protocols. 
Lack of cells was confirmed by hematoxylin/eosin (H/E) and DAPI staining 
(VECTOR). Immunohistochemistry was performed as previously described using 
  30 
anti-α2-laminin antibody (Santa Cruz) and anti-Collagen4 chain α1-2-3-4-5 
antibody (Japan) in order to confirm the maintenance of ECM composition. The 
absence of cellular membrane residuals was confirmed using an anti-MHC I 
antibody (Abcam).  
c- DNA content quantification 
DNA content was quantified by DNeasy Blood & Tissue Kit (Qiagen), to check the 
acellularity of matrices. Briefly, KAMs were dried, minced, weight and digested 
overnight in Proteinase K. After lysis of the samples, DNA was separated from RNA 
through centrifugation using silica-gel columns. The obtained DNA was quantified 
by NanoDrop (Roche) measurements and it was separated in a 1.5% 
agarose/ethidium bromide gel and visualized using Blue/Orange Loading Dye 
(Promega, San Luis Obispo, CA). 
2. CELL CULTURE 
a- Expansion of human Amniotic Fluid (AF) Total Cell Population 
Under Institutional Review Board approval of Children’s Hospital Los Angeles, 
human amniotic samples were obtained from discarded amniocentesis fluid 
between 15 and 20 weeks of gestation. Samples with normal male karyotype and 
normal fetal ultrasound were collected from discarded cultures (Genzyme 
Pasadena, CA). Cells were expanded in Tissue Culture Dishes (BD Falcon, Franklin 
Lakes, NJ) with Chang’s media (α MEM, 20% Chang B and 2% Chang C) (Irvine 
Scientific, Santa Ana, CA), L-Glutamine 20% of ES-FBS (Gibco/Invitrogen, Carlsbad, 
CA) and 1% of antibiotic (Pen/Strep, Gibco/Invitrogen, Carlsbad, CA). 
b- Immunoseparation of CD24+OB-Cadherin+ population from whole Amniotic 
Fluid 
A positive population from AF for both CD24 (Abcam) and OB-Cadherin (Abcam) 
was selected by two further immunoseparation using standard magnetic cell sorting 
(Miltenyi Biotech, Germany) following manufacturer's instructions. The total cell 
population was incubated with these two antibodies for 20 min at 4° C on shaking 
condition, followed by a second incubation with immunomagnetic microbeads for 
15 min at 4° C followed by immunoseparation by MS columns (Miltenyi Biotech, 
Germany). Positive population was replated on Tissue Culture dishes with Chang’s 
Media for subsequent expansion.  
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c- Analysis and characterization by immunohistochemistry of CD24+OB-Cadherin+ 
population 
Between passages 4 and 5, cells previously seeded in chamber slides were fixed in 
4% paraformaldehyde and stained as following described. Cells were treated for 30 
min with hydrogen peroxidase, blocked in a solution of 3% BSA in PBS for 10 min at 
room temperature (RT) and incubated for 60 min with primary antibody. Bound 
primary antibodies were detected by a RT 30 min incubation with the suitable 
secondary antibody and revealed by DAB. 
 
3. CD24+ OB-CADHERIN+ CELLS: KAM CULTURES  
300 µm slides of KAMs were obtained using Vibratome (Leica). Sections were 
washed in PBS added with 10% Pen/Strep (Gibco) and placed at the bottom of a 25 
cm2 flask. Slides were kept in PBS overnight and placed in ES-FBS 
(Gibco/Invitrogen, Carlsbad, CA) 3 h before seeding.  
First antibody Company Diluition Secondary antibody 
Aq1 Santa Cruz 1:100 ImmPRESS Universal Antibody anti-
rabbit Ig/anti-mouse Ig (Vector, MP 
7500) 
Aq2 Santa Cruz 1:50 Biotinylated Rabbit Anti-Goat IgG 
Antibody (Vector BA5000) 
Peanut agglutinin Vector 15 μg/mL Biotinylated Rabbit Anti-Goat IgG 
Antibody (Vector BA5000) 
Nephrin Santa Cruz 1:50 Biotinylated Rabbit Anti-Goat IgG 
Antibody (Vector BA5000) 
WT1 Santa Cruz 1:50 ImmPRESS Universal Antibody anti-
rabbit Ig/anti-mouse Ig (Vector, MP 
7500) 
Podocalyxin Invitrogen 1:50 ImmPRESS Universal Antibody anti-
rabbit Ig/anti-mouse Ig (Vector, MP 
7500) 
Vimentin Santa Cruz 1:50 Biotinylated Rabbit Anti-Goat IgG 
Antibody (Vector BA5000) 
PDGFRβ Abcam 1:50 ImmPRESS Universal Antibody anti-
rabbit Ig/anti-mouse Ig (Vector, MP 
7500) 
VEGF Abcam 1:50 ImmPRESS Universal Antibody anti-
rabbit Ig/anti-mouse Ig (Vector, MP 
7500) 
Von Willebrand 
Factor 
Santa Cruz 1:50 Biotinylated Rabbit Anti-Goat IgG 
Antibody (Vector BA5000) 
Human nuclei Acris 1:100 ImmPRESS Universal Antibody anti-
rabbit Ig/anti-mouse Ig (Vector, MP 
7500) 
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Before seeding, CD24+ OB-Cadherin+ cells (106 cells/cm2) were trypsinized, 
centrifuged at 1500 rpm for 5 min and labelled with the cell tracker CM-Dil 
(Molecular Probes), following manufacturer's instructions. CM-Dil is a membrane 
stain well retained through fixation/permeabilization processes and allows tracking 
of cells after injection. Briefly, cells were resuspended in 500 µl PBS and incubated 
with a working solution of Cm-Dil solution of 1 mg/mL for 5 min at 37°C, followed 
by an incubation of 15 min at 4°C. Cells were finally rinsed three times with PBS. 
The medium was mantained in agitation using a magnetic stirrer starting from 48 h 
from seeding. After 7, 14 and 21 days of culture, seeded KAMs were embedded in 
paraffin as previously described. The presence of CD24+ OB-Cadherin+ cells was 
confirmed by H/E and DAPI staining (VECTOR). To detect renal markers, 
immunohistochemistry was performed as above described.  
The rating of proliferation was determined by PCNA Staining Kit (Invitrogen) 
following manufacture’s instruction. Briefly, deparaffinized and rehydrated slides 
were treated with  blocking solution for 10 min and with biotinylated mouse anti-
PCNA primary antibody for 1 h. Rinsed sections were incubated with streptavidin-
peroxidase solution and at last stained with chromogen DAB solution and 
hematoxylin.  
3. IN VIVO EXPERIMENTS 
All the procedures described and animal protocols were approved by the IACUC at 
Children's Hospital Los Angeles.  
Male 2 months old nude mice (J:Nu, Jackson Laboratories) were divided into 2 
groups: 
- group 1: received not seeded KAMs (n=4) 
- group 2: received  KAMs seeded with CD24+ OB-Cadherin+ cells 7 days after 
seeding (n=4) 
The mice were carefully anesthetized using isofluorane inhalation method. Once 
satisfactory anesthesia was achieved, the mice were prepped using clorhexedine. A 
small approximate 1 cm dorsal lumbotomy incision was made, the kidney carefully 
delivered via the incision. A microvascular clamp was placed across the hilum 
preventing blood flow to the kidney. A small longitudinal incision was made along 
the lateral border of the kidney into the renal cortex. A 300 μm section of KAM 
repopulated or not with renal progenitor cells was inserted into this cortical defect. 
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The defect was closed with 6-0 interrupted polydioxanone suture. The 
microvascular clamp was removed. Once hemostasis was confirmed, the kidney was 
replaced into the retroperitoneum, the incision closed with polypropylene suture 
(Taper C-1, size 5-0, 90 cm), and the mice recovered from anaesthesia. The animals 
were maintained on a heating pad throughout the period of anaesthesia. Ophthalmic 
ointment was placed in each eye to prevent corneal drying; 0.1 mg/kg of 
buprenorphine was administered subcutaneously. 
Mice were sacrified after 1, 2, 3, 6 months by CO2 inhalation and KAM implanted 
kidney collected and rinsed in PBS. Samples were embedded in paraffin and stained 
with H/E and DAPI (VECTOR) staining as previously described. 
Immunohistochemistry was performed as above mentioned with minor 
modifications. Deparaffinized and rehydrated slides were treated for 30 min with 
hydrogen peroxidase, they were blocked in a solution of 3% BSA in PBS for 10 min 
at room temperature (RT) and incubated for 60 min with first primary antibody. 
Bound primary antibodies were detected by a RT 30 min incubation with the 
suitable secondary antibody and revealed by Red DAB. After washing, slides were 
incubated with the second primary  antibody (against Human Nuclei or Human 
Mithocondria) for 1 h at RT and then with the suitable secondary antibody 
(Universal Antibody anti-rabbit Ig/anti-mouse Ig,Vector, MP 7500).  At last, stain 
was developed with DAB and nuclei stained with hematoxylin.  
Kidney was delivered through a dorsal lumbotomy incision (A). The hilum was clamped and a 
small incision was made into the renal cortex (B). A 300 µm KAM slide was insert into the 
cortical defect (C). The incision was closed (D,E) and the microclamp removed (F). 
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Collagen fibers were detected by Masson staining Kit (Sigma), which was performed 
following manufacture’s instruction. Briefly, deparaffinized and rehydrated slides 
were treated with Bouin’s solution for 1 h at 56°C and washed in running tap water. 
Sections were stained in working Weigert’s Iron Hematoxylin Solution for 5 min. 
Rinsed slides were treated with Biebrich Scarlet-Acid Fuchsin and then placed in 
Phosphomolybdic/phosphotungstic acid solution for 5 min. Sections were treated 
with Aniline Blue Solution for 5 min and placed in acetic acid for 2 min. Then, slides 
were dehydrate to xylene and mounted with balsam.  
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RESULTS 
 
 
1. KIDNEY ACELLULAR MATRICES 
Four cycles of detergent-enzymatic treatment were needed to completely remove cells, 
as confirmed by H/E (Fig. 1 B) and DAPI staining (Fig. 1 D). KAMs maintained the 
structure of native kidney (Fig. 1A), in particular the glomerular basement membrane 
was well visible (Fig. 1B).   
 
 
 
 
 
 
 
 
 
 
 
 
Immunohystochemistry revealed the absence of cell membrane antigens MHC I in 
KAMs (Fig. 2 B), normally present in native tissue (Fig. 2 A). 
 
 
 
Figure 1. H/E (A, B; magnification x200) and DAPI (C, D; magnification x200) 
staining before (A, C) and after (B, D) 4 cycles of detergent-enzymatic treatment. 
Arrows indicate glomerular basement membranes.  
Figure 2.  Immunohystochemistry performed using anti-MHC I antibody before (A) 
and after 4 cycles of detergent-enzymatic treatment (B). Magnification x400 
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The maintenance of ECM proteins was confirmed by immunohistoschemistry 
performed using anti-collagen type IV chains I (Fig. 3 A, D), II (Fig. 3 B, E), III (Fig. 3 
C, F), IV (Fig. 3 G, L), V (Fig. 3 H, M) and laminin α2 (Fig. 3 I, N) antibodies. KAMs  
(Fig. 3 D, E, F, L, M, N) showed all glomerular basement membrane proteins, as 
native kidney (Fig. 3 A, B, C, G, H, I).  
The amount of residual DNA content after decellularization was quantified as 
shown in Fig. 4. Although bands of DNA were not visible after separation on 1.5% 
agarose gel (Fig. 4 A), 30.27 ± 11.3 ng DNA/mg dry weight were determined in 
KAMs compared to 2544.43 ± 97.67 ng DNA/mg dry weight found in native kidney 
(Fig. 4 B). 
Figure 3. Immunoistochemistry of native kidney (A, B, C, G, H, I) and KAM (D, E, F, L, M, N) performed 
using anti-collagen type IV chain I (A, D), II (B, E), III (C, F), IV (G, L), V (H, M; magnification x1000) 
and laminin α2 antibodies (I, N; magnification x400). 
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2. CELL CULTURE 
The cell population positive for CD24 and OB-Cadherin was successfully isolated 
from whole AF and cultured under the conditions described above.  Selected cells 
presented a typical fibroblast shape (Fig. 5).  
 
 
 
 
 
 
 
CD24+ OB-Cadherin+ cells were previously characterized by RT-PCR for early and 
mature kidney markers (Da Sacco et al, 2010). Cell extracts contained mRNAs for 
Aquaporin 1 (Aq1), Occludin, Nephrin, Lim1, Pax-2 (paired box gene 2), GDNF (Glial 
Cell Line-derived Neurotrophic Factor), and Zo-1 (Zonula Occludens 1).  
Figure 4. Residual DNA content detected by 1.5% agarose/ethidium bromide gel (A) and DNeasy Blood & 
Tissue Kit (B, n= 5). 
Figure 5. Phase contrast microscopy of CD24+ 
OB-Cadherin+ cell cultures (magnification x200). 
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CD24+ OB-Cadherin+ cells expressed Podocalyxin (Fig. 6 A) and VEGF (Fig. 6 B), 
while WT-1 (Wilms tumor protein-1, Fig. 6 C), Aq1 (Fig. 6 D), Aq2 (Fig. 6 E) and 
Peanut Agglutinin (Fig. 6 F) were not detected. 
 
3. CD24+ OB-CADHERIN+ CELLS/KAM CULTURES 
CD24+ OB-Cadherin+ cells were seeded onto 300 µm KAM slides. Cells engrafted 
the biomaterial and were able to migrate inside it, as shown by DAPI staining 7 (Fig. 
7 A), 14 (Fig. 7 B) and 21 (Fig. 7 C) days after seeding.  
 
Cell engraftment was shown by SEM analysis (Fig.8). In particular, renal progenitors 
were able to rearrange and merge (Fig. 8 B) and shown foot processe buds (Fig. 8 
C). 
 
 
  
Figure 6. Immunohistochemistry of CD24+ OB-Cadherin+ cells Podocalyxin (A), VEGF (B), WT-1 
(C), Aq1 (D), Aq2 (E) and Peanut Agglutinin (F) expression (magnification x200).  
Figure 7. DAPI staining of CD24+ OB-Cadherin+ cell/KAM cultures 7 (A), 14 (B) and 21 (C) 
days after seeding (magnification x100) 
  39 
 
 
 
Besides, PCNA staining demonstrated that CD24+ OB-Cadherin+ cells were able to 
proliferate till 14 d after seeding (Fig. 9 A, B), on the contrary, cell growth seemed to 
stop at 21 days, as determined by lack of staining  (Fig. 9 C). 
 
CD24+ OB-Cadherin+ cells seeded onto KAMs were characterized by 
immunohistochemistry. At each endpoint renal progenitors expressed VEGF, 
Podocalyxin and Aq1 (Fig. 10), but not Aq2, Peanut Agglutinin and WT1 (data not 
shown).  
 
 
 
 
 
 
 
 
 
 
Figure 9. PCNA staining of CD24+ OB-Cadherin+ cells/KAM culture 7 (A), 14 (B) and 21 (C) 
days after seeding (magnification x400). 
Figure 8. SEM analysis of CD24+ OB-Cadherin+ cell/KAM cultures 7 days after seeding. Arrows 
indicate foot processe buds. 
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4. IN VIVO EXPERIMENTS 
KAM alone and KAM plus cells were intrarenal implanted in nude mice. Group 1 
received only KAM while group 2 received KAM seeded with CD24+ OB-Cadherin+ 
cells, 7 days after seeding. At each endpoint, in both groups KAMs were largely 
repopulated by host cells, presented tubular-like structures and blood vessels, as 
shown by H/E staining (Fig. 11).    
Figure 10. Immunohistochemistry of CD24+ OB-Cadherin+ cell/KAM cultures performed using anti-
Aq1 (A, B, C), -Podocalyxin (D, E, F), -VEGF (G, H, I) antibodies 7 (A, D, G), 14 (B, E, H) and 21(C, 
F, I) days after seeding (magnification x400). 
7 days 14 days 21 days 
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Figure 11. H/E staining. A, C, E, G: group 1; B, D, F, H: group 2. A, B: 1 month; C, D: 2 
months; E, F: 3 months; G, H: 6 months (magnification x200). Arrows indicate tubular-like 
structures and blood vessels.  
KAM KAM/ CD24+ OB-Cadherin+ cells 
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One month after surgery both groups presented endothelial cells and blood vessels 
inside the graft, as demonstrated by immunohistochemistry performed using anti-
von Willebrand factor (Fig. 12 A, B) and CD31 (Fig. 12 C, D) antibodies. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In group 2, the permanence of CD24+ OB-Cadherin+ cells was revealed by human 
nuclei staining. Human cells were still present at all timepoints, but their number 
seemed to decrease over the time (Fig. 13).  
Immunohistochemistry performed against different mature renal markers were 
performed in order to evaluate CD24+ OB-Cadherin+ cells differentiation.  
Aq1, Aq2 and Peanut Agglutinin were considered as markers of differentiation into 
tubular cells.  
In group 1, Aq1 positive cells were present only 6 months after intrarenal 
implantation (Fig. 14 G). On the contrary, in group 2, this marker was visible at each 
endpoint. A double staining performed using both anti-human nuclei and anti-Aq1 
Figure 12. KAM (A, C) and KAM plus cells (B, D) immunohistochemistry 
performed using anti-von Willebrand factor (A, B) and anti-CD31 (C, D) 
antibodies (magnification x400).  Arrows indicate positive staining. 
Figure 13. Immunohistochemistry performed on KAM plus cells, 1 (A), 2 (B), 3 (C), 6 (D) months 
after surgery using anti-human nuclei antibody (magnification x400).  
KAM KAM/ CD24+ OB-Cadherin+ cells 
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antibodies demonstrated that Aq1 was expressed by both CD24+ OB-Cadherin+ 
cells and host cells migrated inside the scaffold (Fig. 14 B, D, F, H).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 14. Immunohistochemistry performed using anti-Aq1 antibody on KAM graft (A, C, E, 
G) and KAM plus CD24+OB-Cadherin+ cells (B, D, F, H) 1 (A,B), 2 (C, D), 3 (F, G), 6 (H, I) 
months after surgery. B, D, F and H were obtained using both anti-Aq1 and ant-human nuclei 
antibodies (magnification x400). Arrows indicates double staining positive cells. 
KAM KAM/ CD24+ OB-Cadherin+ cells 
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Similar results were obtained for Aq2. Indeed, the protein was immunodetected in 
both human and host cell in KAM plus cells starting from 1 month, while staining 
was negative in KAM (Fig. 15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Immunohistochemistry performed using anti-Aq2 antibody on KAM (A, C, E, G) 
and KAM plus CD24+OB-Cadherin+ cells (B, D, F, H) 1 (A,B), 2 (C, D), 3 (F, G), 6 (H, I) 
months after surgery. B, D, F and H were obtained using both anti-Aq2 and anti-human nuclei 
antibodies (magnification x400). Arrows indicate double staining positive cells. 
KAM KAM/ CD24+ OB-Cadherin+ cells 
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Besides, human Aq2 positive cells were shown to migrate into the native kidney and 
integrate into native tubuli (Fig. 16). 
 
 
 
 
 
 
 
 
 
 
In KAM grafts Peanut Agglutinin was not detected (Fig. 17 A, C, E, G), whereas only 
murine cells expressed this marker in KAM plus CD24+OB-Cadherin+ graft (Fig. 17 
B, D, F, H).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Aq2-human nuclei double staining of KAM plus CD24+OB-
Cadherin+ cells 6 months after surgery (magnification 400x). 
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Figure 17. Immunohistochemistry performed using anti-Peanut Agglutinin antibody on KAM (A, 
C, E, G) and KAM plus CD24+OB-Cadherin+ cells (B, D, F, H) 1 (A,B), 2 (C, D), 3 (F, G), 6 (H, 
I) months after surgery. B, D, F and H were obtained using both anti-Peanut Agglutinin and anti-
human nuclei antibodies (magnification x400). Arrows indicate Peanut Agglutnin positive staining. 
KAM KAM/ CD24+ OB-Cadherin+ cells 
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To verify podocyte differentiation, immunoreactivity against Podocalyxin and WT1 
antibodies was evaluated. 
In group 2, both human and murine cells expressed Podocalyxin (Fig 18 B, D, F, H) 
and WT1 (Fig 19 B, D, F, H) 1 month after implantation, while in group 1 
Podocalyxin appeared at 3 months (Fig. 18 E, G) and WT1 at 6 months (Fig. 19 E, G).  
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Figure 18. Immunohistochemistry performed using anti-Podocalyxin antibody on KAM (A, C, 
E, G) and KAM plus CD24+OB-Cadherin+ cells (B, D, F, H) 1 (A,B), 2 (C, D), 3 (F, G) and 6 
(H, I) months after surgery. B, D, F and H were obtained using both anti-Podocalyxin and anti-
human nuclei antibodies (magnification x400). Arrows indicated double staining. 
KAM/ CD24+ OB-Cadherin+ cells KAM 
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Figure 19. Immunohistochemistry performed using anti-WT1 antibody on KAM (A, C, E, G) and 
KAM plus CD24+OB-Cadherin+ cells (B, D, F, H) 1 (A,B), 2 (C, D), 3 (F, G) and 6 (H, I) months 
after surgery. B, D, F and H were obtained using both anti-WT1 and anti-human mitochondria 
antibodies (magnification x400). Arrows indicate WT1 staining in KAM and WT1-Human 
Mitochondria double staining in KAM plus cells graft. 
KAM/ CD24+ OB-Cadherin+ cells KAM 
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DISCUSSION 
 
 
This work has demonstrated that KAMs are able to support proliferation and 
differentiation of amniotic fluid renal progenitor cells. 
To obtain KAMs various decellularization protocols have been tested. Detergents, such as 
SDS and Triton X100 (Nakayama et al, 2010; Orlando et al, 2012), appeared not suitable 
because they disrupted collagen structure and lead to incomplete cell removal (data not 
shown). On the contrary, using Meezan method with minor modifications, KAMs 
maintained the native architecture and composition. In particular, both glomerular 
basement membrane and the filtering membrane protein composition were well 
preserved. The decellularization treatment satisfied established parameters for DNA 
content: lacking of visible nuclei after DAPI staining, having less than 50 ng/mg AM dry 
weight and having all residual DNA fragments be less than 200 base pair in size (Crapo et 
al, 2011; Reing et al, 2010). The lack of antigenic epitopes associated with cell 
membranes demonstrated the non-immunogenicity, which is necessary to avoid, or at 
least minimize, adverse immune responses by allogeneic or xenogeneic recipients.  
KAMs revealed to be a suitable scaffold for renal progenitor cells. Indeed, cells engrafted 
the biomaterial and were able to migrate inside it. 
 Cells seeded onto KAMs proliferated till 14 days from seeding and maintained the 
expression of VEGF and Podocalyxin, markers used for podocyte identification.  
Furthermore, SEM analysis shown that cells seeded into KAM presented foot processes 
buds, which are peculiar podocyte features.  These results agree to Leapley et al (2009), 
that demonstrated that KAM allows fetal cortical renal cells to proliferate maintaining 
podocyte progenitor phenotype. 
Without the use of pro-differentiation agents, KAMs have been shown to drive ESC 
differentiation towards the early steps of renal differentiation (Ross et al, 2009). On the 
contrary, in this study, when seeded into KAM without any inductive factor, renal 
progenitors from amniotic fluid expressed mature proximal tubular marker, such as Aq1. 
More investigations will be needed to demonstrate whether Aq1 positive cells could 
express other proximal tubular markers, as CD13 and Angiotensinogen.  
To further evaluate the differentiative potential of KAMs, grafts composed of KAM with 
or without cells were intrarenal implanted into nude mice. Host cells largely repopulated 
KAMs grafts. Murine cells migration confirmed that KAMs presented biocompatible 
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structural features. However, migrated cells did not express tubular or podocyte 
markers till 3-6 months after surgery, although at earlier timepoints most of them 
presented PDGFRβ (data not shown), demonstrating their mesangial origin. The delayed 
migration of cells expressing tubular or podocyte markers could be promoted by KAM 
degradation products that have been shown to have chemotactic and mitogenic effects 
on cells (Badylak et al, 2011).  
 Grafts composed of KAMs plus cells shown the presence of differentiation markers just 1 
month after surgery. Differentiated cells were both murine and human. It can be 
supposed that murine cells migrated earlier than in KAM grafts because renal 
progenitors remodel and degrade KAM that may release soluble molecules regulating 
cells motility. Besides, renal progenitors could produce a variety of paracrine factors that 
can enhance cell migration and engraftment (Li et al, 2010). Intrarenal environment, as 
expected, promoted renal progenitor cell differentiation. CD24+ OB-Cadherin+ cells 
were shown to express proximal tubular (Aq1), collector duct (Aq2) and distal tubular 
(Peanut Agglutinin) markers. Moreover, they expressed WT1, commonly present in 
developing renal vesicles and podocytes, as well as VEGF and Podocalyxin. The co-
expression of the three markers would confirm the differentiation of cells into podocyte 
lineage. CD24+ OB-Cadherin+ cells potentiality to differentiate into different renal 
mature cells was expected because CD24 and OB-Cadherin are co-expressed by 
uninduced Metanephric Mesenchyme, the embryonic layer that gives rise to the entire 
nephron in adult life.  
Interestingly, human CD24+ OB-Cadherin+ cells were also able to migrate outside the 
scaffold and integrate into host kidney. In particular, as native papilla cells, Aq1 positive 
human cells were shown to integrate into host renal tubules (Curtis et al, 2008).  
Overall, these results demonstrated that KAMs obtained by Meezan protocol, 
maintaining ECM structure, could be a valuable tool to study both in vitro and in vivo 
differentiation towards renal cell phenotype.  
Furthermore, these preliminary data encourage us to evaluate whether this approach 
could be useful to enhance the function of hypoplastic kidneys. 
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PART 2: Evaluation of blood vessel substitutes composed by AMs 
and ECs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  55 
MATERIALS AND METHODS 
 
 
1. AORTA ACELLULAR MATRICES 
a- Preparation 
All the procedures described and animal protocols were approved by the CEASA at 
University of Padova. CEASA is University Ethical Animal Use Committee on charge 
of overseeing Padova University animal programs, animal facilities and policies, 
ensuring appropriate care, ethical use and humane treatment of animals. 
Male Lewis rats (3 months old) were sacrificed using CO2 inhalation as 
recommended by IACUC and abdominal aorta segments were collected and rinsed 
with PBS. 
Aorta acellular matrices (AAMs) were prepared by the Meezan method (Meezan et 
al, 1975) with minor modifications. Briefly, aortas were processed with distilled 
water for 72 h at 4˚C, 4% sodium deoxycholate (Sigma, St. Louis, MO, USA) for 4 h 
and 2,000 kU deoxyribonuclease I (DNase-I) (Sigma) in 1 M NaCl (Sigma) for 3 h. 
This treatment was repeated twice times till the decellularization was completed. 
Between the two decellularization cycles, aortas were treated with Collagenase IV 
(0.05% in PBS) at 37°C for 1 min in order to remove the endothelium.  
b- Evaluation of AAMs by histological and immunohistochemistry staining and 
Scanning Electron Microscopy 
Histological samples and analysis were performed as previously described. Lack of 
cells was confirmed by hematoxylin/eosin (H/E) and DAPI staining (VECTOR).  
Movat pentachromic staining was performed following manufacturer's instruction 
(Diapath). Briefly, deparaffinized sections were treated with alcian blue, which 
stains mucin and background. Elastic fibers were purple-black stained by 
hematoxilyn, collagen was yellow by treatment with fuchsin and alcoholic safran 
solution stained black nuclei.  
Immunohistochemistry was performed as previously described using anti-MHC I 
and II antibody (Abcam) to confirm the absence of cellular membrane residuals. 
AAM samples were fixed with 4% gluteraldehyde in 0.1 M cacodylate buffer (pH 
7.2) and dehydrated. After critical point drying and gold sputtering, they were 
examined by a scanning electron microscope (SEM; Stereoscan-205 S, Cambridge, 
UK). 
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2.  CELL CULTURES  
a- Skin microvascular ECs: isolation and characterization 
Dermis biopsies were harvested from male Lewis rats (3-5 months old). Specimens 
were rinsed in PBS, minced and subsequentially digested enzimatically with 0.25% 
Collagenase B (Roche), and 0.25% Dispase II (Roche), for 1 h at 37°C. Not digested 
dermis was removed using a cell strainer (100 µm, BD Falcon). Cells were seeded in 
Tissue Culture Petri Dishes (BD Falcon) previously conditioned with Fibronectin (1 
µg/cm2, BD Biosciences) in MV2 endothelial media (PromoCell). When cells were 
almost confluent, they were detached and immunoseparated using Dynabeads M-
450 (Invitrogen) previously conditioned with a monoclonal antibody against CD31 
(AbD Serotec) following manufacter’s instruction. Briefly, cells were incubated with 
magnetic beads previously conditioned with the antibody for 30 min at 4 °C (5 
beads for each cell). A magnetic field was applied to the cells for 5 min. CD31-
positive cells tied to the beads through the antibody remained attached to the 
magnet. CD31-negative cells were discarded. ECs were replated in Tissue Culture 
Petri Dishes previously conditioned with MV2 endothelial media. Only cells 
between passages 1 and 4 were used.  
The maintenance of endothelial markers was confirmed by immunofluorescence 
analysis using antibody against CD31 (Santa Cruz Biotecnology, 1:100) and von 
Willebrand Factor (1:400, Abcam). Briefly, cells were fixed with 4% formalin. Then, 
they were incubated for 1 h with 10% horse serum in PBS followed by 1 h 
treatment with the solution of the primary antibody. After rinsing with PBS, cells 
were treated with the secondary antibody for 30 min and with Flurescein Avidin 
DCS 1:500 in HEPES 10 mM and NaCl 0.15 M for 10 min. Nuclei were recognized by 
DAPI staining.  
b- ECs/AAM cultures 
ECs (4x105/cm2) were seeded onto the luminal surface of AAMs, previously treated 
with FCS for 3 h.  Cultures were maintained for 72 h in MV2 media and then fixed 
for histological analysis or in vivo implanted. 
3. IN VIVO EXPERIMENTS 
Female Lewis rats (3 months old) were carefully anesthetized using isofluorane 
inhalation method (3% isofluorane carried by oxygen, 1 L/min). Each recipient 
animal underwent a median laparotomy incision. After peritoneal incision, animals 
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received 5 mg/mL Tramadol (Contramal) intraperitoneally. After systemic 
heparinisation (70 U/Kg) and proximal and distal clamping of the abdominal aorta, 
a segment of 1 cm length was removed. The same segment was replaced by only 
AAM (n=7) or AAM plus ECs (n=9). Anastomoses were performed with 8-0 or 9-0 
interrupted polypropylene suture (Ethicon).  Once the incision closed, rats were 
recovered from anaesthesia. Animals received an antibiotic (Terramicina , 60 
mg/kg) on the 3rd and 6th day after surgery and analgesics (Contramal , 5 mg/kg), 
for 3 days postoperatively. No anticoagulants or antiplatelets were administered 
post-operatively. 
Animals were sacrificed by Phenobarbital administration either 1 (n=8) or 3 
months (n=8) after implantation. Arterial conduits were explanted and histological 
and SEM analyses were performed, as previously described.  
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RESULTS 
 
 
1. AORTA ACELLULAR MATRICES 
Two cycles of detergent-enzymatic treatment were needed to completely remove cells. 
Between the two decellularization cycles aortas were treated with Collagenase IV to detach 
the endothelial layer, still present at the end of the first treatment (Fig. 1 C). Collagenase 
digestion allowed us to decrease the treatment duration that would compromise the 
mechanical properties of the biomaterial. H/E staining confirmed the absence of cells  (Fig. 
1D). AAMs maintained elastic fibers, while connective component was modified compared 
to native tissue (Fig. 1A) by a longer detergent treatment (Fig. 1C).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunohystochemistry revealed the absence in AAMs (Fig. 2 C, D) of both MHC I 
and II cell membrane antigens, normally present in native tissue (Fig. 2, A, B). 
Figure 1 H/E staining (A,C,D; magnification x200) and SEM analysis (B, D, E; 
magnification x200) of not treated abdominal aorta (A,B), the same after one 
(C,D) or 2 (D,E) detergent-enzymatic treatments.  
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2. CELL CULTURES 
a- Skin microvascular endothelial cells: isolation and characterization 
In 2 weeks, 6 millions of microvascular endothelial cells were obtained from a 2 cm2 
skin biopsy (Fig. 3 A, B).  CD31 (Fig. 3C) and von Willebrand factor (Fig.3D) stainings 
confirmed the maintenance of the endothelial phenotype till the fourth culture 
passage.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Immunohystochemistry performed using anti-MHC I (A,C) and II (B,D) 
antibodies before(A,B) and after 2 detergent-enzymatic treatments. Magnification x200. 
Figure 3 Cultures of skin microvascular endothelial cells. Phase-contrast  
microscopy (A,B, magnification x100). Immunohystochemistry performed using 
anti CD-31 (C) and anti  von-Willebrand factor antibodies (D). Magnification x400 
anti-MHCI anti-MHCII 
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b- ECs/AAM cultures 
ECs were seeded into the luminal surface of AAMs. At 72 h ECs adhered on AAMs, 
provided a continuous monolayer (Fig. 4 A, B, C) and maintained their phenotype 
(Fig. 4 D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. IN VIVO EXPERIMENTS 
AAMs or AAMs plus cells were implanted into abdominal aorta of female Lewis rats.  
Animals have been sacrificed 1 or 3 months after surgery.  
Group A: rats receiving only AAMs 
Seven rats received only AAMs as aorta interposition graft: 4 animals were sacrificed 
after 1 month and 3 after 3 months. All animals survived.  
Explanted grafts presented a higher diameter than host vessel  (Fig. 5 A, B).  
One month after surgery, only the borderline with the native vessel was 
reendothelized (Fig.  5 C), while the surface in the middle of the graft shown collagen 
fibers and platelets adhesion (Fig. 5 D). 
Only one graft presented almost a continuous ECs monolayer (about 90% of surface 
area) and didn’t present thrombi. However, histological analysis shown intimal 
Figure 4 SEM (A, B; magnification x300, x1000) and DAPI staining (C, 
magnification x 200) of ECs/AAM cultures at 72h. The EC phenotype was 
confirmed by immunohystochemistry performed using an anti-von 
Willebrand factor antibody (D, magnification x400).  
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hyperplasia and a thick adventitial layer, while elastic fibers were well organized (Fig. 
5 E).  
Analogous results were obtained analysing samples collected three months after 
surgery. Two grafts still presented exposed collagen fibers remnants and ubiquitous 
platelet adhesion, while only one presented luminal surface almost completely 
reendothelizated. Moreover, histological analysis shown a severe intimal hyperplasia. 
However, no graft presented any thrombi.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group B: rats receiving AAMs/ECs 
Nine rats received AAM plus ECs as aorta interposition graft: 4 animals were 
sacrificed after 1 month, while 5 rats after 3 months. All animals survived and no 
thrombi were observed in all samples. 
The diameter of the graft was the same as the host one (Fig. 6 A, B). All grafts were 
completely reendothelized with no platelet adhesion (Fig. 6 C, D). Although elastic 
Figure 5 AAM grafts 1 month after surgery. Explanted graft (A,B); SEM of 
luminal surface (C,D); Movat staining (E, magnification x200) 
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fibers were visible, the tunica media appeared thinner than the native one. As 
observed in AAM grafts, adventitial layer was hyperplastic. 
 
 
 
 
 
 
Three months after surgery grafts composed of AAM plus ECs appeared to be 
narrowed. Grafts were completely reendothelized with no platelet adhesion (Fig. 7 
A, B). However, Movat staining shown a reduced elastic fiber layer (Fig. 7 C) 
comparated to the native one (Fig. 7 D), a moderate intimal hyperplasia and a tunica 
adventitia similar to the host one. 
 
 
 
 
Figure 6 AAM plus ECs grafts 1 month after surgery. Explanted graft (A,B); SEM of luminal 
surface (A, B); Movat staining (F, magnification x200). 
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Figure 7 AAMs plus ECs grafts 3 months after surgery (A, B, C): SEM of luminal surface (A, B); 
Movat staining (C, magnification x200). Movat staining of native abdominal aorta (D). 
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DISCUSSION 
 
 
This work has demonstrated that AAMs previously seeded with skin microvascular 
ECs could be used as vessel substitutes.  AAMs were obtained following Meezan 
method with minor modifications. In previous studies, this immuno-enzymatic 
protocol has already shown to obtain suitable AMs that have been used both in 
preclinical and in clinical applications (Gilbert et al, 2006). This decellularization 
process induces the loss of the major histocompatibility complex markers, but 
maintains angiogenic factors, such as b-FGF and TGF-β (Ribatti et al, 2003; Conconi 
et al, 2004 bis and 2005 bis). Thus, AMs can present angiogenic activity that is an 
important factor for the in vivo integration of the tissue substitutes. AMs obtained 
by this protocol can support in vitro adhesion, growth and function of several cell 
types (Burra et al 2004; Dettin et al 2005; Conconi et al 2005), while in vivo AMs can 
act as a template allowing the ingrowth of the host cells and can be remodeled in a 
living tissue (Parnigotto PP et al, 2000; Marzaro M et al, 2006; Conconi MT et al, 
2004). Moreover, they represent preformed structures whose length and gauges 
can be choice according to the dimension of the segment to be repaired. Another 
advantage is the possibility to have easy and unlimited availability of inexpensive 
grafts containing tissue-specific proteins. On June 2008 the first tissue engineered 
trachea, created using a AM human donor trachea as scaffold seeded with patient’s 
own cells, was implanted into a 31-year-old woman’s left main bronchus 
(Macchiarini et al, 2008). 
In this work, AAMs maintained the three different layers as non-treated aorta and 
lacked of antigenic epitopes. Nowadays, several groups tested various AMs as 
vascular graft (Clarke et al, 2001; Conklin et al, 2002).  Although they shown a good 
patency, the acellular luminal surface of these decellularized matrices without 
endothelial cells (ECs) lining carries a substantial risk for thrombosis when exposed 
directly to the blood flow. Our study confirmed these observations. Indeed, at 1 and 
3 months, AAM grafts were not completely reendothelized, presented thrombi and 
intimal hyperplasia. Skin microvasculature could be an alternative source of ECs: 
skin biopsy is a moderately invasive procedure and in a short time allowed to obtain 
a large amount of cells from small samples. One month after implantation grafts 
composed by AAM and ECs could be histologically compared to native vessels, 
demonstrated a good patency and no thrombi. After three months, a moderate 
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intimal hyperplasia was detected and grafts presented the tunica media thinner 
than the one of native vessel. Although the substitutes appeared narrowed, patency 
was good and no thrombotic processes were visible. It can be supposed that the 
remodelling process was still in progress. Thus, longer endpoints should be 
investigated to determine the in vivo remodelling of the scaffold. However, these 
results agreed to the ones obtained by Kaushal et al (2001) seeding porcine iliac 
AMs with endothelial progenitors from peripheral blood. To improve the outcome 
of reconstructive surgery, alternative approaches should be evaluated. For example 
co-seeding of ECs and SMCs may be a suitable strategy to maintain the artery wall 
structure, but it will take a longer time to obtain the substitute (Neff et al, 2006).  
In the present study we attempted to construct vessels in a clinically relevant time 
frame. Important to clinical application is having conduit available in a wide range 
of sizes on short notice. Despite other vascular regeneration techniques already 
used in clinical practise, which takes 4-6 weeks to create an implantable grafts (Neff 
et al, 2006), this protocol lead to obtain a vascular substitute in only 2 weeks. 
Besides this technique might eliminate the need to remove healthy vessels for 
collecting autologous endothelial cells. 
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CONCLUSION 
 
 
Overall, this work has shown that the detergent-enzymatic treatment allows to 
obtain AMs possessing the main features of the native tissue. For this reason, tissue-
specific AMs were able to act both as suitable environment for in vitro and in vivo 
growth and differentiation studies and as biomaterial to develop vessel substitutes. 
In particular, KAMs supported in vitro both proliferation and differentiation of renal 
progenitors from amniotic fluid into tubular-like and podocyte-like cells.  
Furthermore, in vivo experiments shown that progenitors expressed mature renal 
markers, attracted inside KAMs differentiated murine cells and integrated into 
tubular host structures. These results could suggest to evaluate this approach for 
the enhancement of the function of hypoplastic kidneys.  
On the other hand, AAMs seems to be an interesting biomaterial for vascular TE. 
The lack of reendothelization, leading to intimal hyperplasia and increased 
incidence of thrombosis observed in AAMs grafts, have indicated the need to 
provide in vitro an endothelial coverage of decellularized tissue. Indeed, grafts 
composed of AAM and skin microvasculature ECs shown good patency and no 
thrombi. Although these grafts appeared narrowed and a moderate hyperplasia has 
been detected in the inner layer, they presented two main advantages: they were 
obtained into a clinically relevant time frame and eliminated the need to remove 
healthy vessels for collecting autologous ECs.  
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